# Open-Label, Extension Study to 810P202

> **NCT01416064** · PHASE2 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 78 (actual)

## Conditions studied

- Impulsive Aggression Comorbid With ADHD in Children

## Interventions

- **DRUG:** Molindone

## Key facts

- **NCT ID:** NCT01416064
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-01
- **Final completion:** 2013-02
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2017-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416064, "Open-Label, Extension Study to 810P202". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01416064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*